Evidence map›Paper›PMID 42883724›Full record

ArticleInternational journal of molecular sciences2026

Validation of Aptamer-Protein Interactions by Biolayer Interferometry: A Study of 88 Candidate Molecules.

Elizaveta S Ershova, Natalia V Pozdnyakova, Aleksandra Yu Egorshina, Elena V Yakushenko, Igor V Dobrokhotov, Nadezhda P Lyamina, Bella B Gagulaeva, Alexey Moskalev

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elizaveta S ErshovaPetrovsky National Research Center of Surgery, Institute of Biology of Ageing and Healthy Longevity Medicine with Clinic of Predictive Medicine, 119435 Moscow, Russia.ORCID 0000-0003-1206-5832
Natalia V PozdnyakovaSistemaBioTech, LLC, 1-ya Kuryanovskaya Str. 34, 109235 Moscow, Russia.ORCID 0000-0003-0938-3258
Aleksandra Yu EgorshinaSistemaBioTech, LLC, 1-ya Kuryanovskaya Str. 34, 109235 Moscow, Russia.ORCID 0000-0001-7818-1161
Elena V YakushenkoPetrovsky National Research Center of Surgery, Institute of Biology of Ageing and Healthy Longevity Medicine with Clinic of Predictive Medicine, 119435 Moscow, Russia.ORCID 0000-0002-5048-9188
Igor V DobrokhotovPetrovsky National Research Center of Surgery, Institute of Biology of Ageing and Healthy Longevity Medicine with Clinic of Predictive Medicine, 119435 Moscow, Russia.
Nadezhda P LyaminaPetrovsky National Research Center of Surgery, Institute of Biology of Ageing and Healthy Longevity Medicine with Clinic of Predictive Medicine, 119435 Moscow, Russia.ORCID 0000-0001-6939-3234
Bella B GagulaevaPetrovsky National Research Center of Surgery, Institute of Biology of Ageing and Healthy Longevity Medicine with Clinic of Predictive Medicine, 119435 Moscow, Russia.ORCID 0000-0002-1415-3070
Alexey MoskalevPetrovsky National Research Center of Surgery, Institute of Biology of Ageing and Healthy Longevity Medicine with Clinic of Predictive Medicine, 119435 Moscow, Russia.ORCID 0000-0002-3248-1633

Funding

The Ministry of Education and Science of the Russian Federation 125090910141-5
6 · The paper itself

Abstract

An aptamer's low mass confines the label-free response to hundredths of a nanometer, where artifacts mimic binding yet yield computable dissociation constants. To define and test a priori criteria distinguishing binding from artifact, 88 computationally designed aptamers against seven human proteins were studied by biolayer interferometry in two orthogonal configurations, with control antibodies. Six criteria, fixed in advance, are reported as a priori decision rules, not validated requirements. Control antibodies validated 6 of 8 preparations; for the other 68 pairs, the maximum response was 0.019-0.219 nm, bounding

Indexed as

Aptamers, NucleotideInterferometryProteinsHumansProprotein Convertase 9Protein BindingAptamers, NucleotideProprotein Convertase 9Proteinsbinding validationbiolayer interferometryBLIcomputational oligonucleotide designdata quality controlDNA aptamersnegative resultnonspecific bindingOctet

Identifiers

PMID42883724
PMCPMC13664908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.